The mRNA platform that proved itself against COVID earned its second major approval — Moderna mFlusiva for influenza — while new Alzheimer research found tau damages neurons through an entirely separate mechanism from tangle formation. The bottom line: this week in longevity delivered translatable results, from senolytic combinations to centenarian microbes to blood tests that see disease a decade before symptoms appear.
The FDA approved the first mRNA-based flu vaccine, with Phase 3 data showing improved efficacy against H3N2 strains versus egg-based comparators. The platform allows faster strain reformulation when seasonal predictions change.
A study found hyperphosphorylated tau directly interferes with neuronal DNA double-strand break repair — causing genomic instability as a separate mechanism from the neurofibrillary tangles previously considered tau's primary pathology.
A systematic review synthesising over 350 studies found dietary protein restriction consistently activates mTOR inhibition and autophagy across multiple model organisms, with early human data showing reduced inflammatory markers.
Mathematical modelling calculated that even if all reversible aging hallmarks were eliminated, unavoidable somatic DNA mutations would cap median human survival at roughly 146 to 194 years.
Single-cell analysis of the human hippocampus identified coordinated shifts in immune cell populations, genome organisation, and gene regulation across cell types between midlife and older age.
A mouse study tested low-dose navitoclax combined with quercetin, clearing senescent cells at doses too low to cause the platelet depletion that has limited navitoclax clinical development.
Clostridium scindens — over-represented in centenarian microbiomes — reduced intestinal permeability and inflammatory markers in aged mice after colonisation, producing secondary bile acids that modulate intestinal immune tone.
A clinical study found PhenoAge acceleration independently predicted 30-day post-surgical mortality after controlling for surgical complexity, comorbidities, and chronological age. Patients in the highest quartile had 3.4x the mortality rate.
A Nature Aging study validated a 12-protein blood panel detecting metabolic liver disease a median of 16 years before clinical diagnosis, performing consistently across sex and BMI subgroups.
A controlled study found COVID infection reactivates latent Epstein-Barr and herpes simplex viruses in a meaningful proportion of cases, with reactivation correlating with long COVID symptom persistence.
One email a week. The ten things in AI that mattered, and why. Choose your channel.